Drugs / ABCD
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04225195 | Jan 2020 → Apr 2022 | candidiasis, invasive, invasive aspergillosis | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07239765 | Jul 2021 → Apr 2024 | fungal infectious disease | CSPC Ouyi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-04-01 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - "AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗
“AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION” OBTAINS DRUG REGISTRATION APPROVAL |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-04-01 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - "AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABCD | “Amphotericin B cholesteryl sulfate complex for injection(ABCD)” NCT04225195 ↗ |
| Known as | Amphotericin B cholesteryl sulfate complex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04225195 ↗ |
| Route | Intravenous | “intravenous treatment with ABCD” NCT04225195 ↗ |